Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Dice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly Buyout

Dice stock skyrocketed Tuesday after Eli Lilly pledged to buy the immunology-focused biotech company for $2.4 billion.

Investors Business Daily

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million

Eli Lilly inked a gene-editing collaboration with Verve Therapeutics that gave the young biotech "pharma validation."

Investors Business Daily

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Investors Business Daily

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

The Conversation

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review

The major indexes retreated for most of the week on banking fears, but rebounded Friday on a strong jobs report and bank stocks roaring back.

Investors Business Daily

Eli Lilly says an experimental drug slows Alzheimer's worsening

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced.

WEKU

‘Remarkable’ drug reduces Alzheimer’s decline, study shows

Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.

Al Jazeera

New Alzheimer’s drug slows cognitive decline by 35%, trial results show

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

The Guardian - UK

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

Washington (AFP) - US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects.

AFP

Eli Lilly says experimental drug slows Alzheimer's worsening

Eli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease

The Independent UK

'Remarkable' Alzheimer drug reduces cognitive decline, results show

Washington (AFP) - US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts.

AFP

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

Investors Business Daily

Lilly Has Plans For Possible Anti-Obesity Medication. Here's How To Make Money With LLY Options

This trade is a neutral to bullish position and anticipates the stock holding above 390 over the summer term.

Daily Record

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

The Independent UK

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates

Eli Lilly stock surged Thursday after diabetes drug Mounjaro blew past sales projections and led to promising weight loss in a Phase 3 study.

Businessweek

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

The Street

Jim Cramer Bluntly Schools Stock-Buyers On 3 'Amazing American' Companies

The CNBC host offers some pointed thoughts.

ABC News

Why EV conversions could become more mainstream for classic cars through to 4WD utes

From classic cars to 4WD utes, Noah Wasmer wants EV conversions to become mainstream.

Investors Business Daily

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.